Blog

FDA Adds Warnings to SGLT2 Inhibitor Labels

This month the Food and Drug Administration (FDA) has added new warnings to the Type 2 diabetes medications known as SGLT2 Inhibitors.  In May of 20-15 FDA issued warnings that the use of these drugs could cause too much acid to be present in the blood, a condition called ketoacidosis. The updated warnings issued in December 2015 reinforce that patients and their doctors should be on the look-out for signs and symptoms of ketoacidosis which include nausea, vomiting, abdominal pain, tiredness and trouble breathing.

The new warnings now caution that serious urinary tract infections may also occur with the use of these medications.  Symptoms of this infection are a feeling of burning on urination, a need to urinate often, pain in the lower part of the abdomen or pelvis, fever and possibly blood in the urine.  FDA recommends that a person who experiences any of these symptoms while on an SLGT2 inhibitor should contact their doctor immediately.

The brand names of FDA approved SLGT2 Inhibitors are:  Invokana, Invokamet, Farixga, Xigduo XR, Jardiance, Gylxambi and Synjardy.

If you or a loved one has experienced side effects and been injured by one of these medications, please contact the Locks Law Firm.